^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Gastroesophageal Cancer |
| Drug: | Tevimbra (tislelizumab-jsgr) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
154P - Investigation of PD-L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with VENTANA PD-L1 (SP263) assay and Combined Positive Score (CPS)
Published date:
09/14/2020
Excerpt:
Associations between CPS and TIC scoring methods, and potential correlations with efficacy, were investigated in patients with GEA from the tislelizumab first-in-human study….At a 17.4-month median follow-up, patients with TIC ≥5% or CPS ≥1 showed survival benefit. Inter-reader and -laboratory overall agreement for TIC ≥5% were 99% (95% CI, 98-100) and 96% (95% CI, 94-98), respectively...
Trial ID:
